European Respiratory Society Annual Congress 2013

Abstract Number: 1131 Publication Number: P3077

Abstract Group: 11.2. Pleural and Mediastinal Malignancies Keyword 1: Biomarkers Keyword 2: Inflammation Keyword 3: Pleura

Title: Pleural eicosanoids in patients with lung cancer

Prof. Dr Jae Hwa 9957 Cho jaehwa.cho@inha.ac.kr MD¹, Prof. Sunghyouk 9958 Park psh@snu.ac.kr², Prof. Dr Haesung 9959 Nam hsnam@gmail.com MD¹, Prof. Dr Seungmin 9960 Kwak smkwak@inha.ac.kr MD¹, Prof. Dr Jeongseon 9961 Ryu jsryu@inha.ac.kr MD¹ and Prof. Dr Honglyeol 9962 Lee hllee@inha.ac.kr MD¹. ¹ Internal Medicine, Inha University Hospital, Incheon, Republic of Korea and ² College of Pharmacy, Seoul National University, Seoul, Republic of Korea .

Body: Introduction: Malignant pleural effusion can be diagnosed by cytology and biopsy. The accuracy of pleural cytology was 96.5%, but diagnostic discrepancies were 3.5%. The prostaglandins and leukotrienes involved in cancer progression. We investigated the possibility of biomarkers of malignant pleural effusion using NMR-based metabolomics approach. Materials and methods: We prospectively collected pleural effusion fluids from patients with lung cancer and benign lung diseases (tuberculosis and pneumonia) at Inha University Hospital (Incheon, Republic of Korea) between January 2012 and September 2012. Liquid chromatography-tandem mass spectrometry was used for analysis. We detected DHA, AA, 20-carboxy-LTB4, 6-keto-PGE1a, 20-hydroxy LTB4, PGE2, TXB2, LXA4, LTE4, PGA1, 20-HRTR, 11-dehydro-TXB2. Results: Eleven patients with lung cancer and twelve with benign were analyzed. The 20-hydroxy LTB4, LXA4, DHA, AA in pleural fluid were increased in cancer group (p<0.05, respectively). Conclusion: Some of eicosanoids such as AA, 20-carboxy LTB4 might be a role in cancer progression. Further large scaled study will be needed to confirm this findings.